Search results for " Exacerbation"

showing 10 items of 41 documents

Bacterial-viral load and the immune response in stable and exacerbated COPD: significance and therapeutic prospects.

2016

Silvestro Ennio D’Anna,1 Bruno Balbi,2 Francesco Cappello,3,4 Mauro Carone,2 Antonino Di Stefano21Department of Rehabilitation, Cardiorespiratory Unit, Fondazione Istituto G. Giglio di Cefalù, 2Pneumology Unit and Laboratory of Cytoimmunopathology of Heart and Lung, Fondazione Salvatore Maugeri, IRCCS, Veruno (NO) and Cassano delle Murge (BA), 3Human Anatomy Section, Department of Experimental Biomedicine and Clinical Neuroscience, University of Palermo, Palermo, Italy; 4Euro-Mediterranean Institute of Science and Technology, Palermo, ItalyAbstract: Chronic obstructive pulmonary disease (COPD) is characterized by persistent airflow limitation and an abnormal inflammatory respon…

0301 basic medicinePulmonary and Respiratory MedicinePulmonary diseasemicrobiomeReview03 medical and health sciencesPulmonary Disease Chronic Obstructive0302 clinical medicineImmune systemexacerbationsmedicineHumansMicrobiomeRespiratory systemlcsh:RC705-779COPDImmunity CellularLungseverity of COPDbusiness.industryBiomarkers; COPD phenotype; Exacerbations; Microbiome; Severity of COPD; Pulmonary and Respiratory Medicine; Public Health Environmental and Occupational Health; Health PolicyHealth PolicyPublic Health Environmental and Occupational HealthbiomarkersExacerbationlcsh:Diseases of the respiratory systemBiomarkerGeneral MedicineViral Loadmedicine.diseaseBacterial Loadrespiratory tract diseases030104 developmental biologymedicine.anatomical_structure030228 respiratory systemImmunologyDisease ProgressionCOPD phenotypebusinessViral loadRespiratory tractInternational journal of chronic obstructive pulmonary disease
researchProduct

Asthma control in severe asthmatics under treatment with omalizumab: A cross-sectional observational study in Italy

2015

Few data are available on the proportion of asthmatics achieving a good asthma control (according GINA guidelines) and on the level of airway inflammation during omalizumab treatment. The aim of this cross-sectional national observational study was to assess the level of control (according to GINA guidelines) achieved in a group of asthmatics on omalizumab treatment, and to characterize the factors that influence the lack of control. We studied 306 asthmatics under omalizumab treatment for a median of 32 months (range 4-120). The level of control according to GINA was good in 25.2%, partial in 47.1% and poor in 24.5% of patients (data were missing for the remaining 3.2%). Comparison between…

AdultMalePulmonary and Respiratory Medicinemedicine.medical_specialtyExacerbationCross-sectional studyOmalizumabOmalizumabComorbiditySettore MED/10 - Malattie Dell'Apparato RespiratorioExhaled nitric oxide; Exacerbations; Comorbidities; Asthma; Omalizumab; ControlSeverity of Illness IndexComorbiditiesExacerbationsExhaled nitric oxideInternal medicineSeverity of illnessControlMedicineAnti-Asthmatic AgentHumansPharmacology (medical)Anti-Asthmatic AgentsInflammation MediatorAsthmaRespiratory Function TestAgedCross-Sectional Studiebusiness.industryBiochemistry (medical)ExacerbationMiddle Agedmedicine.diseaseComorbidityAsthmaRespiratory Function TestsCross-Sectional StudiesItalyExhaled nitric oxidePhysical therapyObservational studyAsthma; Comorbidities; Control; Exacerbations; Exhaled nitric oxide; Omalizumab; Adult; Aged; Anti-Asthmatic Agents; Asthma; Comorbidity; Cross-Sectional Studies; Female; Humans; Inflammation Mediators; Italy; Male; Middle Aged; Omalizumab; Respiratory Function Tests; Severity of Illness Index; Pulmonary and Respiratory Medicine; Biochemistry (medical); Pharmacology (medical)FemaleComorbiditieInflammation Mediatorsbusinessmedicine.drugHuman
researchProduct

Higher serum levels of periostin and the risk of exacerbations in moderate asthmatics

2016

BACKGROUND: In asthma, exacerbations and poor disease control are linked to airway allergic inflammation. Serum periostin has been proposed as a systemic biomarker of eosinophilic inflammation. This pilot study aims at evaluating whether in patients with moderate asthma, higher baseline levels of serum periostin are associated with a greater risk of exacerbation. METHODS: Fifteen outpatients with moderate allergic asthma were recruited. Serum concentrations of periostin were assessed (ELISA) at baseline, and the frequency of asthma exacerbations was recorded during a one-year follow-up. RESULTS: Patients (M/F: 10/5, mean age of 47.6 ± 11.0 years) had mean ACQ score of 5.5 ± 4.2 and FEV1%pre…

Allergymedicine.medical_specialtyExacerbationSerum biomarkerPeriostinSettore MED/10 - Malattie Dell'Apparato RespiratorioBiochemistryAllergic inflammation03 medical and health sciences0302 clinical medicineInternal medicinemedicineAsthmatic patient030212 general & internal medicineAirway inflammation; Asthma; Exacerbation; Periostin; Serum biomarkerAsthmabusiness.industryResearchOrganic ChemistryExacerbationmedicine.diseaseSerum biomarker Asthma Periostin Exacerbation Airway inflammationAsthmaPeriostin030228 respiratory systemImmunologyBiomarker (medicine)businessAirwayAirway inflammation
researchProduct

Determinants of between-hospital variations in outcomes for patients admitted with COPD exacerbations: findings from a nationwide clinical audit (AUD…

2015

Background Previous studies have demonstrated significant variability in the processes of care and outcomes of chronic obstructive pulmonary disease (COPD) exacerbations. The AUDIPOC is a Spanish nationwide clinical audit that identified large between-hospital variations in care and clinical outcomes. Here, we test the hypothesis that these variations can be attributed to either patient characteristics, hospital characteristics and/or the so-called hospital-clustering effect, which indicates that patients with similar characteristics may experience different processes of care and outcomes depending on the hospital to which they are admitted. Methods A clinical audit of 5178 COPD patients co…

Clinical auditMalePediatricsmedicine.medical_specialtyPulmonologymedia_common.quotation_subjectPsychological interventionMEDLINEPulmonary diseaseDisease clusterPatient ReadmissionAUDIPOCPulmonary Disease Chronic ObstructivemedicineOdds RatioHumansHospital Mortalitymedia_commonAgedOriginal PaperCOPDVariablesClinical Auditbusiness.industryHospitals PublicGeneral MedicineOdds ratioMiddle Agedmedicine.diseasePrognosisCOPD exacerbationsSpainEmergency medicineFemalebusiness
researchProduct

Roflumilast improves corticosteroid resistance COPD bronchial epithelial cells stimulated with toll like receptor 3 agonist

2015

Chronic obstructive pulmonary disease (COPD) is characterised by chronic pulmonary inflammation punctuated by periods of viral exacerbations. Recent evidence suggests that the combination of roflumilast with corticosteroids may improve the compromised anti-inflammatory properties of corticosteroids in COPD. We analyzed differential and combination anti-inflammatory effects of dexamethasone and roflumilast N-oxide in human bronchial epithelial cells (HBECs) stimulated with viral toll like receptor (TLR) agonists. Lung tissue and HBECs were isolated from healthy (n = 15), smokers (n = 12) and smokers with COPD (15). TLR3 expression was measured in lung tissue and in HBECs. IL-8 secretion was …

CyclopropanesMaleAnti-Inflammatory AgentsDrug ResistanceAminopyridinesDexamethasonePulmonary Disease Chronic ObstructiveRoflimilastAdrenal Cortex HormonesToll like receptorsCells CulturedCOPDSmokingMiddle Agedmedicine.anatomical_structureBenzamidesCorticosteroidViral exacerbationDrug Therapy CombinationFemalePulmones - Enfermedadesmedicine.drugSignal TransductionAgonistPulmonary and Respiratory Medicinemedicine.medical_specialtymedicine.drug_classCorticosteroid resistanceBronchiInternal medicinemedicineCOPDHumansInterleukin 8DexamethasoneRoflumilastAgedLungbusiness.industryResearchInterleukin-8Epithelial CellsAparato respiratoriomedicine.diseaserespiratory tract diseasesToll-Like Receptor 3EndocrinologyPoly I-CCase-Control StudiesTLR3businessRespiratory Research
researchProduct

Patients Withdrawing Dupilumab Monotherapy for COVID-19-Related Reasons Showed Similar Disease Course Compared With Patients Continuing Dupilumab The…

2022

N/A

Dupilumab TherapyAntibodies Monoclonal Humanized; Disease Progression; Humans; Treatment Outcome; COVID-19; Dermatitis AtopicDermatitisAtopic dermatitis.DermatologyDupilumabAntibodies Monoclonal HumanizedAntibodiesAtopicDermatitis AtopicSettore MED/35MonoclonalImmunology and AllergyHumanshumanHumanizedAtopic dermatitistreatment outcome Antibodies Monoclonal HumanizedCOVID-19Treatment OutcomeCOVID-19 Dupilumab Therapydisease exacerbationDisease ProgressionSettore MED/35 - MALATTIE CUTANEE E VENEREEHumanmonoclonal antibody atopic dermatiti
researchProduct

Global Initiative for Asthma (GINA) Strategy 2021 - Executive summary and rationale for key changes

2021

Funder: Global Initiative for Asthma

ExacerbationRespiratory SystemINHALED CORTICOSTEROIDSCritical Care and Intensive Care MedicineAsthma managementSINGLE-INHALERDOUBLE-BLINDRisk Factorsimmune system diseasesAdrenal Cortex HormonesRELIEVER THERAPYFormoterol FumarateMedicine and Health SciencesImmunology and AllergyAnti-Asthmatic AgentsChild11 Medical and Health SciencesLung functionMILD PERSISTENT ASTHMAExecutive summaryBiologic therapiesCombined Modality TherapyLUNG-FUNCTIONChild PreschoolPractice Guidelines as TopicPerspectiveDisease ProgressionDrug Therapy Combinationmedicine.drugPulmonary and Respiratory MedicineAdultmedicine.medical_specialtyBUDESONIDE/FORMOTEROL MAINTENANCEAdolescentMild asthmaMEDLINEInhaled corticosteroidsCONTROLLED-TRIALSkills trainingGINA Strategy 2021: Executive SummaryBUDESONIDE-FORMOTEROLAdministration InhalationmedicineHumansasthma preventionIntensive care medicineSEVERE EXACERBATIONSAsthmaasthma diagnosisbusiness.industryPatient AcuityInfantasthmamedicine.diseaseAsthmarespiratory tract diseasesSelf Carewf_140Formoterolwf_100businessasthma management
researchProduct

Resolved versus confirmed ARDS after 24 h: insights from the LUNG SAFE study

2018

Purpose: To evaluate patients with resolved versus confirmed ARDS, identify subgroups with substantial mortality risk, and to determine the utility of day 2 ARDS reclassification. Methods: Our primary objective, in this secondary LUNG SAFE analysis, was to compare outcome in patients with resolved versus confirmed ARDS after 24 h. Secondary objectives included identifying factors associated with ARDS persistence and mortality, and the utility of day 2 ARDS reclassification. Results: Of 2377 patients fulfilling the ARDS definition on the first day of ARDS (day 1) and receiving invasive mechanical ventilation, 503 (24%) no longer fulfilled the ARDS definition the next day, 52% of whom initial…

MaleARDSmedicine.medical_treatmentlnfectious Diseases and Global Health Radboud Institute for Molecular Life Sciences [Radboudumc 4]ARDS reassessment; ARDS Survival; Berlin criteria ARDS; Persisting ARDS;Critical Care and Intensive Care Medicineassisted ventilation0302 clinical medicineRisk Factors030212 general & internal medicinerisk factor AdultTidal volumecomparative studyeducation.field_of_studyRespiratory Distress SyndromeMortality rateRemission Inductiontidal volumeARDS reassessment; ARDS Survival; Berlin criteria ARDS; Persisting ARDS; Critical Care and Intensive Care MedicineARDS reassessmentartificial ventilationclinical trialimmunosuppressive treatmentadult respiratory distress syndromeMiddle AgedARDS SurvivalMonte Carlo methodmedicine.anatomical_structureclassificationpositive end expiratory pressureCardiologyDisease ProgressionSOFA scoredisease severityFemaleAdultmedicine.medical_specialtyPopulationdisease classificationArticleNO03 medical and health sciencesremissionlength of stayAnesthesiologyInternal medicinemedicinepneumoniaSequential Organ Failure Assessment ScoreHumanshumaneducationAgedMechanical ventilationhospital mortalityLungbusiness.industryRisk Factordisease associationRespiratory Distress Syndrome AdultPersisting ARDSmedicine.diseasemajor clinical studymortalityRespiration Artificialbreathing rate030228 respiratory systemdisease exacerbationBerlin criteria ARDSbusinessIntensive care medicine
researchProduct

Effects of different physical therapy programs on perceived health status in acute exacerbation of chronic obstructive pulmonary disease patients: a …

2017

To evaluate the repercussion of different physical therapy interventions on the perceived health status of chronic obstructive pulmonary disease (COPD) patients during acute exacerbation.Randomized controlled trial. Patients were assigned to: control group (standard medical treatment), controlled breathing + range of motion exercises group or Resistance exercises group. Perceived health status was assessed at baseline and discharge using the EuroQol-5D (EQ-5D) questionnaire. Clinical profile of patients was evaluated at baseline for descriptive purposes.Ninety patients were randomized into the groups. Perceived health status improved significantly in all groups. Significant differences were…

MaleAcute exacerbation of chronic obstructive pulmonary diseasemedicine.medical_specialtyExacerbationVisual analogue scalePsychological interventionBreathing Exerciseslaw.inventionDiagnostic Self EvaluationDiagnostic Self EvaluationPulmonary Disease Chronic Obstructive03 medical and health sciences0302 clinical medicineRandomized controlled trialQuality of lifelawSurveys and QuestionnairesmedicineHumans030212 general & internal medicinePhysical Therapy ModalitiesAgedCOPDbusiness.industryRehabilitationMiddle AgedSymptom Flare Upmedicine.diseaseSelf CareTreatment Outcome030228 respiratory systemQuality of LifePhysical therapyExercise Movement TechniquesFemalebusinessDisability and Rehabilitation
researchProduct

From Global Initiative for Chronic Obstructive Lung Disease (GOLD) Guidelines to Current Clinical Practice

2006

Background: The Global Initiative for Chronic Obstructive Lung Disease (GOLD) guidelines have been promulgated to improve the management of chronic obstructive pulmonary disorder (COPD). Objective: To evaluate the extent to which the current therapeutic approach to COPD conforms to GOLD guidelines. Methods: This was a multicentre observational study of elderly COPD patients enrolled for acute care in general medicine or geriatric wards in tertiary hospitals in Italy in April 2002. Our series consisted of 471 patients >64 years of age consecutively admitted for acute exacerbations of COPD to wards participating in the study. Data describing drugs used prior to exacerbation and prescribed at …

MaleAgingmedicine.medical_specialtyDrug IndustryPharmacological therapyGuidelines as Topicurologic and male genital diseasesPulmonary Disease Chronic ObstructivePharmacotherapyOdds RatiomedicineHumansMulticenter Studies as TopicPharmacology (medical)Practice Patterns Physicians'Intensive care medicineAgedCOPDbusiness.industryRespiratory diseaseTiotropium bromidemedicine.diseaseDrug UtilizationObstructive lung diseaserespiratory tract diseasesClinical PracticeLung diseasePhysical therapyFemaleGuideline AdherenceAcute Exacerbation Tiotropium Methylxanthine Tiotropium Bromide Cumulative Illness Rate ScaleGeriatrics and Gerontologybusinessmedicine.drugDrugs & Aging
researchProduct